Market-Moving News for February 23rd
IPOWER, Inc. IPW | 1.13 1.11 | -0.88% -1.77% Pre |
Novo Nordisk A/S Sponsored ADR Class B NVO | 40.81 41.06 | +3.79% +0.61% Pre |
Vanda Pharmaceuticals Inc. VNDA | 7.27 7.27 | -0.68% 0.00% Pre |
VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And For Schizophrenia In Adults
NVO: -15% | Novo Nordisk's Headline Results From REDEFINE 4 Phase 3 Trial Of Cagrisema Shows 23% Weight Loss After 84 Weeks Of Treatment, Also Cagrisema 2.4/2.4 mg Did Not Meet The Primary Endpoint Of Showing Non-inferiority On Weight Loss Compared To Tirzepatide 15 mg At 84 Weeks
IPW: -16% | IPW stock has given up its prior gain. iPower shares were trading higher. The company reported Q2 financial results.
